Tofacitinib: a janus kinase inhibitor for rheumatoid arthritis
Prescriber2017Vol. 28(8), pp. 30–32
Citations Over Time
Abstract
Tofacitinib (Xeljanz) is an oral janus kinase (JAK) inhibitor indicated for the second‐line treatment of moderate to severe active rheumatoid arthritis in adults. This article discusses its properties, efficacy and adverse effects.
Related Papers
- → Tofacitinib, an Oral Janus Kinase Inhibitor: Perspectives in Dermatology(2017)27 cited
- → Herpes zoster as a cause of atypical chronic ulcerations associated with tofacitinib(2018)5 cited
- → Poor phase 4 safety results for tofacitinib raise questions about JAK inhibitors(2021)3 cited
- → Tofacitinib: a janus kinase inhibitor for rheumatoid arthritis(2017)1 cited
- Tofacitinib (CP-690,550): A First-In-Class Janus Kinase (JAK) Inhibitor for the Treatment of Rheumatoid Arthritis(2014)